Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

News

Infinitopes Doses First Patient With Precision Off-the-Shelf Therapeutic Cancer Vaccine ITOP1

VISTA trial evaluates a precision therapeutic vaccine in an immunologically favourable treatment window for oesophageal cancer

Patient enrolment begins in PARTNERS trial to identify the first effective treatments for Bundibugyo virus disease

An international collaboration between the Institut National de Recherche Biomédicale (INRB) Democratic Republic of the Congo, the Institute of Tropical Medicine (ITM), Antwerp, and the University of Oxford, the trial will evaluate potential therapies for Bundibugyo virus disease.

PSI’s continued involvement in UK-PHRST to reinforce epidemic preparedness globally

The expanded UK Public Health Rapid Support Team, including institutions from the UK, Africa and Southeast Asia, has now received £18m in funding for the next five years.

Oxford Bundibugyo ebolavirus vaccine candidate receives CEPI backing

The Coalition for Epidemic Preparedness Innovations (CEPI) has announced today that it will urgently accelerate the development of three investigational vaccines targeting the Bundibugyo ebolavirus that has caused a rapidly spreading epidemic in the Democratic Republic of the Congo (DRC) and neighbouring Uganda, including one being developed by the Oxford Vaccine Group at the University of Oxford.

Media spotlight: PSI experts on Bundibugyo Ebola vaccines and treatments

Several UK and global outlets have covered Oxford’s response to the Bundibugyo Ebola virus outbreak currently affecting the DRC and Uganda.

Statement on vaccine efforts relating to the Bundibugyo Ebolavirus outbreak in the DRC

In response to the current Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo, the Oxford Vaccine Group (OVG) is working urgently with Oxford’s own Clinical BioManufacturing Facility and the Serum Institute of India Pvt. Ltd. (SIIPL), to rapidly produce and scale doses of our ChAdOx-based monovalent Bundibugyo Ebolavirus candidate vaccine, ChAdOx1 BDBV.

New rabies vaccine could provide protection for adults and children with a single dose

A new clinical trial led by researchers at the Jenner Institute in collaboration Ifakara Health Institute Tanzania, suggests that a single-dose rabies vaccine could provide safe, long-lasting protection in both adults and children. The research could lead to a simpler, lower-cost approach that could transform rabies prevention in high-risk regions.

Oxford and Serum Institute of India sign IP licence agreement to advance NipahB vaccine candidate

The agreement will enable the Serum Institute of India to support the development, manufacture and potential future supply of the vaccine candidate developed by PSI scientists.

Epigames generate real-life insights to inform the future of pandemic preparedness

Bringing together real environments and simulated outbreak scenarios, the epigames approach combines decision-making, real-time network dynamics and structured incentives.

Pandemic PACT launches new WHO Pandemic and Epidemic Intelligence Funding Tracker dashboard

Pandemic and epidemic intelligence is essential for preventing, detecting and responding to current and future public health threats.

New Oxford-led trial explores if the immune system can be trained to control HIV

Can the immune system be trained to control HIV without continuous medication? A new Oxford-led clinical trial is exploring whether immune-based strategies could support longer-term viral control after stopping antiretroviral therapy.

New review provides insights to inform future Nipah virus clinical trials

The review, which has been published in The Lancet Microbe, addresses critical knowledge gaps, helping to inform the design of future clinical trials and improve patient treatment.

PSI supports the 100 Days Mission Implementation Report’s call to reinvigorate pandemic preparedness research and development

Several PSI activities and initiatives have been identified as contributing to the 100 Days Mission's goal to prepare as much as possible within the first 100 days of a pandemic.

Join us for the International Pandemic Sciences Conference 2026

Co-hosted by PSI and Singapore’s Programme for Research in Epidemic Preparedness and REsponse (PREPARE), this year's conference will take place in Singapore and online from 1 to 3 July 2026.

New toolkit offers practical guidance to tackle stigma in infectious disease outbreaks

Thirty international experts collaborated to produce the ISARIC Anti-Stigma Guidelines: a practical toolkit designed for use in outbreak response planning and delivery.

Ambitious research aiming to develop multivalent vaccines to protect against multiple deadly filoviruses

Working with international partners, scientists across PSI and OVG will design and develop multivalent vaccine candidates with funding from CEPI and Horizon Europe.

Driving the development of new tools to combat Nipah virus outbreaks

PSI’s Nipah Virus Research Day, held on Wednesday, 19 November 2025, showcased promising developments, spanning new insights into Nipah virus biology, clinical trials of vaccines, the development of policy responses, and progress in developing diagnostics and treatments, all of which are helping improve responses to outbreaks of this deadly virus.

International collaboration launches largest-ever therapeutics trial for patients hospitalised with dengue

A landmark international research collaboration has launched the largest clinical trial ever conducted to test therapeutics for moderate-severe dengue, a mosquito-borne viral disease that continues to spread rapidly driven by climate change and globalisation.

World's first Phase II Nipah virus vaccine trial launch

The trial will assess the safety and immune response of the ChAdOx1 NipahB vaccine, developed by PSI scientists, in a region where the virus causes recurrent outbreaks.

First volunteer receives Lassa fever vaccine in cutting-edge Oxford trial

The vaccine developed by PSI researchers aims to advance the fight against Lassa fever virus, a WHO priority pathogen posing a significant public health risk.

Load More